Lipoid pneumonia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(6 intermediate revisions by 2 users not shown)
Line 5: Line 5:
{{CMG}}; {{AE}} {{RG}}
{{CMG}}; {{AE}} {{RG}}
==Overview==
==Overview==
The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between [[Pneumonia|pneumonias]] from different causes and lack of specific marker to distinguish [[Pneumonia|pneumonias]] from each other. In 2019 there was an outbreak of vaping based pulmonary complications.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
 
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In 2019 there was an outbreak of vaping based pulmonary complications.
*The majority of underlying cause of morbidity was lipoid pneumonia.
*The incidence of cases differentiated based on state can be seen on :{{cite web |url=https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html |title=Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping |format= |work= |accessdate=}}
*The [[incidence]] and [[prevalence]] of lipoid pneumonia are underestimated. It is mostly because of similarities between [[Pneumonia|pneumonias]] from different causes and lack of specific marker to distinguish [[pneumonia]] from each other.<ref name="LanspaJones201322">{{cite journal|last1=Lanspa|first1=Michael J.|last2=Jones|first2=Barbara E.|last3=Brown|first3=Samuel M.|last4=Dean|first4=Nathan C.|title=Mortality, morbidity, and disease severity of patients with aspiration pneumonia|journal=Journal of Hospital Medicine|volume=8|issue=2|year=2013|pages=83–90|issn=15535592|doi=10.1002/jhm.1996}}</ref>
*There is no prediction of [[incidence]] of lipoid pneumonia but the [[incidence]] of lipoid pneumonia is approximately 300,000 to 600,000 individuals annually in the United States.<ref name="Marik200122">{{cite journal|last1=Marik|first1=Paul E.|title=Aspiration Pneumonitis and Aspiration Pneumonia|journal=New England Journal of Medicine|volume=344|issue=9|year=2001|pages=665–671|issn=0028-4793|doi=10.1056/NEJM200103013440908}}</ref>


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
*There is no study about prevalence of lipoid pneumonia.
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
 
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].
===Mortality rate===
*Prognosis of lipoid pneumonia is usually indolent, however, it may also be progressive.<ref name="GondouinManzoni1996">{{cite journal|last1=Gondouin|first1=A.|last2=Manzoni|first2=Ph.|last3=Ranfaing|first3=E.|last4=Brun|first4=J.|last5=Cadranel|first5=J.|last6=Sadoun|first6=D.|last7=Cordier|first7=J.F.|last8=Depierre|first8=A.|last9=Dalphin|first9=J.C.|title=Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France|journal=European Respiratory Journal|volume=9|issue=7|year=1996|pages=1463–1469|issn=00000000|doi=10.1183/09031936.96.09071463}}</ref>
*Lipoid pneumonia is not usually a cause of death. Most patients suffer from complications such as [[superinfection]], [[cor pulmonale]] or [[lung cancer]] which may be mortal.<ref name="pmid6625788">{{cite journal| author=Greenberger PA, Katzenstein AL| title=Lipid pneumonia with atypical mycobacterial colonization. Association with allergic bronchopulmonary aspergillosis. | journal=Arch Intern Med | year= 1983 | volume= 143 | issue= 10 | pages= 2003-5 | pmid=6625788 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6625788  }} </ref><ref name="pmid3983869">{{cite journal| author=Dixon C, Bolivar R, Katz R, McMurtrey M| title=Lipoid pneumonia and Mycobacterium fortuitum pulmonary infection: successful treatment with sulfisoxazole. | journal=Tex Med | year= 1985 | volume= 81 | issue= 3 | pages= 57-60 | pmid=3983869 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3983869  }} </ref><ref name="GreenawayCaterson1989">{{cite journal|last1=Greenaway|first1=T. M.|last2=Caterson|first2=I. D.|title=HYPERCALCEMIA AND LIPOID PNEUMONIA|journal=Australian and New Zealand Journal of Medicine|volume=19|issue=6|year=1989|pages=713–715|issn=00048291|doi=10.1111/j.1445-5994.1989.tb00342.x}}</ref><ref name="Casey1961">{{cite journal|last1=Casey|first1=James F.|title=Chronic Cor Pulmonale Associated with Lipoid Pneumonia|journal=JAMA|volume=177|issue=13|year=1961|pages=896|issn=0098-7484|doi=10.1001/jama.1961.03040390010003}}</ref>


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
* Lipoid pneumonia commonly affects children and elderly.<ref name="LanspaPeyrani2015">{{cite journal|last1=Lanspa|first1=Michael J.|last2=Peyrani|first2=Paula|last3=Wiemken|first3=Timothy|last4=Wilson|first4=Emily L.|last5=Ramirez|first5=Julio A.|last6=Dean|first6=Nathan C.|title=Characteristics associated with clinician diagnosis of aspiration pneumonia: A descriptive study of afflicted patients and their outcomes|journal=Journal of Hospital Medicine|volume=10|issue=2|year=2015|pages=90–96|issn=15535592|doi=10.1002/jhm.2280}}</ref>
*There is no racial predilection to [disease name].
* The [[incidence]] of lipoid pneumonia increases with age; the median age at diagnosis is 70-80 years.<ref name="LanspaJones20132">{{cite journal|last1=Lanspa|first1=Michael J.|last2=Jones|first2=Barbara E.|last3=Brown|first3=Samuel M.|last4=Dean|first4=Nathan C.|title=Mortality, morbidity, and disease severity of patients with aspiration pneumonia|journal=Journal of Hospital Medicine|volume=8|issue=2|year=2013|pages=83–90|issn=15535592|doi=10.1002/jhm.1996}}</ref>
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


===Region===
*
*The majority of [disease name] cases are reported in [geographical region].


*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
===Gender===


===Developed Countries===
* There is no gender preference in lipoid pneumonia.<ref name="KimKim2018">{{cite journal|last1=Kim|first1=Chang Ho|last2=Kim|first2=Eun Jin|last3=Lim|first3=Jae Kwang|last4=Yoo|first4=Seung Soo|last5=Lee|first5=Shin Yup|last6=Cha|first6=Seung Ick|last7=Park|first7=Jae Yong|last8=Lee|first8=Jaehee|title=Comparison of exogenous and endogenous lipoid pneumonia: the relevance to bronchial anthracofibrosis|journal=Journal of Thoracic Disease|volume=10|issue=4|year=2018|pages=2461–2466|issn=20721439|doi=10.21037/jtd.2018.04.06}}</ref>


===Developing Countries===
*


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
​


{{WH}}
[[Category:Medicine]]
{{WS}}
[[Category:Pulmonology]]
[[Category: (name of the system)]]
[[Category:Up-To-Date]]
[[Category:Emergency medicine]]

Latest revision as of 22:30, 29 July 2020


Lipoid pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lipoid pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lipoid pneumonia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lipoid pneumonia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lipoid pneumonia epidemiology and demographics

CDC on Lipoid pneumonia epidemiology and demographics

Lipoid pneumonia epidemiology and demographics in the news

Blogs on Lipoid pneumonia epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lipoid pneumonia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between pneumonias from different causes and lack of specific marker to distinguish pneumonias from each other. In 2019 there was an outbreak of vaping based pulmonary complications.

Epidemiology and Demographics

Incidence

  • In 2019 there was an outbreak of vaping based pulmonary complications.
  • The majority of underlying cause of morbidity was lipoid pneumonia.
  • The incidence of cases differentiated based on state can be seen on :"Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping".
  • The incidence and prevalence of lipoid pneumonia are underestimated. It is mostly because of similarities between pneumonias from different causes and lack of specific marker to distinguish pneumonia from each other.[1]
  • There is no prediction of incidence of lipoid pneumonia but the incidence of lipoid pneumonia is approximately 300,000 to 600,000 individuals annually in the United States.[2]

Prevalence

  • There is no study about prevalence of lipoid pneumonia.

Mortality rate

  • Prognosis of lipoid pneumonia is usually indolent, however, it may also be progressive.[3]
  • Lipoid pneumonia is not usually a cause of death. Most patients suffer from complications such as superinfection, cor pulmonale or lung cancer which may be mortal.[4][5][6][7]

Age

  • Lipoid pneumonia commonly affects children and elderly.[8]
  • The incidence of lipoid pneumonia increases with age; the median age at diagnosis is 70-80 years.[9]

Gender

  • There is no gender preference in lipoid pneumonia.[10]

References

  1. ↑ Lanspa, Michael J.; Jones, Barbara E.; Brown, Samuel M.; Dean, Nathan C. (2013). "Mortality, morbidity, and disease severity of patients with aspiration pneumonia". Journal of Hospital Medicine. 8 (2): 83–90. doi:10.1002/jhm.1996. ISSN 1553-5592.
  2. ↑ Marik, Paul E. (2001). "Aspiration Pneumonitis and Aspiration Pneumonia". New England Journal of Medicine. 344 (9): 665–671. doi:10.1056/NEJM200103013440908. ISSN 0028-4793.
  3. ↑ Gondouin, A.; Manzoni, Ph.; Ranfaing, E.; Brun, J.; Cadranel, J.; Sadoun, D.; Cordier, J.F.; Depierre, A.; Dalphin, J.C. (1996). "Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France". European Respiratory Journal. 9 (7): 1463–1469. doi:10.1183/09031936.96.09071463. ISSN 0000-0000.
  4. ↑ Greenberger PA, Katzenstein AL (1983). "Lipid pneumonia with atypical mycobacterial colonization. Association with allergic bronchopulmonary aspergillosis". Arch Intern Med. 143 (10): 2003–5. PMID 6625788.
  5. ↑ Dixon C, Bolivar R, Katz R, McMurtrey M (1985). "Lipoid pneumonia and Mycobacterium fortuitum pulmonary infection: successful treatment with sulfisoxazole". Tex Med. 81 (3): 57–60. PMID 3983869.
  6. ↑ Greenaway, T. M.; Caterson, I. D. (1989). "HYPERCALCEMIA AND LIPOID PNEUMONIA". Australian and New Zealand Journal of Medicine. 19 (6): 713–715. doi:10.1111/j.1445-5994.1989.tb00342.x. ISSN 0004-8291.
  7. ↑ Casey, James F. (1961). "Chronic Cor Pulmonale Associated with Lipoid Pneumonia". JAMA. 177 (13): 896. doi:10.1001/jama.1961.03040390010003. ISSN 0098-7484.
  8. ↑ Lanspa, Michael J.; Peyrani, Paula; Wiemken, Timothy; Wilson, Emily L.; Ramirez, Julio A.; Dean, Nathan C. (2015). "Characteristics associated with clinician diagnosis of aspiration pneumonia: A descriptive study of afflicted patients and their outcomes". Journal of Hospital Medicine. 10 (2): 90–96. doi:10.1002/jhm.2280. ISSN 1553-5592.
  9. ↑ Lanspa, Michael J.; Jones, Barbara E.; Brown, Samuel M.; Dean, Nathan C. (2013). "Mortality, morbidity, and disease severity of patients with aspiration pneumonia". Journal of Hospital Medicine. 8 (2): 83–90. doi:10.1002/jhm.1996. ISSN 1553-5592.
  10. ↑ Kim, Chang Ho; Kim, Eun Jin; Lim, Jae Kwang; Yoo, Seung Soo; Lee, Shin Yup; Cha, Seung Ick; Park, Jae Yong; Lee, Jaehee (2018). "Comparison of exogenous and endogenous lipoid pneumonia: the relevance to bronchial anthracofibrosis". Journal of Thoracic Disease. 10 (4): 2461–2466. doi:10.21037/jtd.2018.04.06. ISSN 2072-1439.

​

Retrieved from "https://www.wikidoc.org/index.php?title=Lipoid_pneumonia_epidemiology_and_demographics&oldid=1640170"